Prostate Cancer & SARM

[Michael Scally MD]

Transition Therapeutics Announces Dosing of First Patient in Phase 2 Study of Drug Candidate TT701
http://finance.yahoo.com/news/transition-therapeutics-announces-dosing-first-200100660.html

TORONTO, April 25, 2016 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) today announced the dosing of the first patient of a Phase 2 study of selective androgen receptor modulator (SARM) drug candidate TT701.

The Phase 2 study will evaluate the efficacy and safety of TT701 in improving the symptoms of androgen deficiency (sexual symptoms, fatigue/low vitality, and physical dysfunction) IN MEN WITH PROSTATE CANCER WHO HAVE UNDERGONE RADICAL PROSTATECTOMY FOR ORGAN-LOCALIZED PROSTATE CANCER.

Brigham and Women's Hospital (BWH) is conducting the investigator-led Phase 2 clinical study which is expected to enroll up to 125 subjects at selected specialized clinical sites including BWH.

The principal investigator for the Phase 2 study is Dr. Shalender Bhasin, Director of the Research Program in Men's Health: Aging and Metabolism at BWH and an internationally recognized endocrinologist with expertise in testosterone biology and men's aging.

Transition's wholly-owned subsidiary, Transition Therapeutics Ireland Limited exclusively licensed worldwide rights to the TT701 drug candidate from Eli Lilly and Company ("Lilly").

 

[Dr JIM]

Transition Therapeutics Announces Dosing of First Patient in Phase 2 Study of Drug Candidate TT701
http://finance.yahoo.com/news/transition-therapeutics-announces-dosing-first-200100660.html

TORONTO, April 25, 2016 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) today announced the dosing of the first patient of a Phase 2 study of selective androgen receptor modulator (SARM) drug candidate TT701.

The Phase 2 study will evaluate the efficacy and safety of TT701 in improving the symptoms of androgen deficiency (sexual symptoms, fatigue/low vitality, and physical dysfunction) IN MEN WITH PROSTATE CANCER WHO HAVE UNDERGONE RADICAL PROSTATECTOMY FOR ORGAN-LOCALIZED PROSTATE CANCER.

Brigham and Women's Hospital (BWH) is conducting the investigator-led Phase 2 clinical study which is expected to enroll up to 125 subjects at selected specialized clinical sites including BWH.

The principal investigator for the Phase 2 study is Dr. Shalender Bhasin, Director of the Research Program in Men's Health: Aging and Metabolism at BWH and an internationally recognized endocrinologist with expertise in testosterone biology and men's aging.

Transition's wholly-owned subsidiary, Transition Therapeutics Ireland Limited exclusively licensed worldwide rights to the TT701 drug candidate from Eli Lilly and Company ("Lilly").

I hope the results further define the risks/benefits ratio of SARM therapy AND further delineate what impact these drugs have on gonadotropin and androgen levels.

I presuppose such assays may be conducted since the study's intent is to investigate the influence of SARMS in prostatectomy patients with sexual dysfunction and their potential benefit toward ameliorating the symptoms of "androgen deficiency"